Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from the U.S. Food and Drug Administration
Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from the U.S. Food and Drug Administration
Article Date
April 2, 2024
This article is featured on another website.
Go to article
April 17, 2026
China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy
China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell…
April 17, 2026
China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy
China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…